ALX Oncology Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALXO research report →
Range $4 – $4
Price Chart
About the company
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
- CEO
- Jason Lettmann
- IPO
- 2020
- Employees
- 48
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on ALXO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $137.03M
- P/E
- -1.17
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.14
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.35%
- ROIC
- -61.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-104,021,000
- Net Income
- $-101,695,000+24.6%
- EPS
- $-1.90+26.4%
- OCF Growth
- +31.0%
- FCF Growth
- +31.1%
- 52W High
- $2.66
- 52W Low
- $0.86
- 50D MA
- $1.28
- 200D MA
- $1.80
- Beta
- 0.40
- RSI (14)
- 44
- Avg Volume
- 1.18M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ALX Oncology said Q1 2026 was a strong execution quarter, highlighted by new ESMO breast data that further supported CD47 as a predictive biomarker for evorpacept and kept both pipeline programs on track.· May 9, 2026
- Evorpacept + zanidatamab showed the strongest activity in centrally confirmed HER2-positive, CD47-high tumors, including a 100% confirmed response rate in 5 patients and one complete response.
- Management said the new data reinforce CD47 as a predictive biomarker, with durability reported at a median 20.2 months DOR and 22.1 months median PFS in the CD47-high subset.
- ASPEN-09 in HER2-positive breast cancer is enrolling well and remains on track for interim top-line data from about 80 patients in mid-2027.
- ALX2004 dose escalation is progressing on plan, with initial safety data expected in the second half of 2026.
- The February financing and new leadership hire, Jeff Knight as Chief Development and Chief Operating Officer, were cited as strengthening execution capacity.
The company did not report revenue or EPS on the call, as it was a clinical-stage update. For the ESMO breast dataset, management and the guest presenter cited a 33% confirmed objective response rate in all 24 patients, 60% ORR in the 10 centrally confirmed HER2-positive patients, and 100% ORR in the 5 patients who were both centrally confirmed HER2-positive and CD47-high (defined retrospectively as 20% or higher membrane staining). In that CD47-high subset, median duration of response was 20.2 months and median PFS was 22.1 months; in the full 24-patient cohort, median DOR was 20 months and median PFS was 3.6 months. Management said ASPEN-09 is on track for interim top-line data from approximately 80 patients by mid-2027, while ALX2004 remains on track for an initial safety readout in the second half of 2026. No quarterly financial guidance was given.
Jason Lettmann framed Q1 as a quarter of strong execution, new data, and a stronger balance sheet. He emphasized that the ESMO breast findings further validate evorpacept’s mechanism and the company’s targeted oncology strategy, and said the team remains excited about both Evo and ALX2004. His tone was upbeat but measured, repeatedly pointing to upcoming catalysts over the next 12 to 18 months and saying both programs remain on track for registrational development by the end of next year.
No CFO spoke on the call, and the company did not provide a detailed financial package or cash balance on the transcript. Management did say the February financing was anchored by strong investors and “further strengthens the balance sheet,” giving the company runway to execute through key milestones over the next year to two years. On the operating side, they highlighted continued enrollment progress in ASPEN-09 and ALX2004 dose escalation, with both programs moving according to plan.
Analysts focused on what would count as compelling ASPEN-09 data, how CD47 testing might be used commercially, and whether the company could pursue accelerated approval. Management said they would view anything north of about 30% ORR and roughly 6 months-plus DOR as strong in this heavily pretreated post-ENHERTU setting, while PFS may be too immature for the mid-2027 interim readout. On regulatory strategy, Barbara Klencke said accelerated approval is not the base case; a Phase III study is more likely, though an extraordinary response rate could reopen that discussion. They also said Ventana is developing a companion diagnostic and that ASPEN-09 should help define the best CD47 cut point before a later-stage trial.
The call provided a clearer biological and clinical story for evorpacept: benefit appears strongest in HER2-positive, CD47-high disease, and the pattern matched what the company has seen in another HER2-positive setting. Management also believes the ongoing ASPEN-09 study is de-risked because it enrolls the same late-line, post-ENHERTU population and is progressing well. The balance sheet was described as stronger after the February financing, and ALX2004 remains an additional near-term value driver.
The data are still from very small subsets, and management repeatedly noted that the CD47 findings need validation in ASPEN-09 before the biomarker can be considered established. They also said PFS may be too immature at the mid-2027 interim readout and that accelerated approval would be difficult unless results are extraordinary. On ALX2004, the company is still in dose escalation, so its risk profile remains early-stage and largely dependent on upcoming safety data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.7%
- Shares Outstanding
- 129.28M
- Float Shares
- 88.78M
of shares held by institutions
98 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 13.01M | 0 |
| Venbio Partners LLC | 12.88M | 0 |
| Blackrock, Inc. | 7.71M | ▲ 313.25K |
| Redmile Group, LLC | 7.39M | ▼ 571.68K |
| Blackstone Inc. | 6.59M | ▲ 767.00K |
| Silverarc Capital Management, LLC | 6.57M | ▲ 821.20K |
| Driehaus Capital Management LLC | 6.03M | ▲ 290.62K |
| Tcg Crossover Management, LLC | 5.66M | ▼ 7.36M |
| Vanguard Capital Management LLC | 4.75M | ▼ 224.61K |
| Marshall Wace, Llp | 3.15M | ▲ 76.72K |
| 5am Venture Management, LLC | 3.06M | 0 |
| Almitas Capital LLC | 2.94M | ▼ 235.40K |
Held by 101 ETFs
Biggest fund positions in ALXO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Lettmann Jason | sell | 2,230 |
| Aug 17, 26 | Wong Shelly | sell | 573 |
| Jul 1, 26 | Wong Shelly | sell | 1,404 |
| Apr 16, 26 | Knight Jeff E. | other | 800,000 |
| Apr 16, 26 | Klencke Barbara | other | 100,000 |
| Apr 13, 26 | Knight Jeff E. | other | 0 |
| Mar 19, 26 | Lettmann Jason | sell | 12,311 |
| Mar 19, 26 | Pinto Shelly | sell | 903 |
| Mar 3, 26 | Klencke Barbara | other | 700,000 |
| Feb 25, 26 | Klencke Barbara | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALXO coverage
Recent articles, reports, and earnings notes.
No research on ALXO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALXO report →ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 16
ALX Oncology to Present at Upcoming Investor Conferences
globenewswire.com · Nov 10
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
globenewswire.com · Sep 28
7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.
defenseworld.net · Sep 4
ALX Oncology to Present at Upcoming Investor Conferences in September
globenewswire.com · Sep 2
5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
defenseworld.net · Aug 26
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
zacks.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.